Excess dietary fructose does not alter gut microbiota or permeability in humans: A pilot randomized controlled study.
Fecal microbiome
excess dietary fructose
fecal metabolome
gut permeability
non-alcoholic fatty liver disease
Journal
Journal of clinical and translational science
ISSN: 2059-8661
Titre abrégé: J Clin Transl Sci
Pays: England
ID NLM: 101689953
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
02
2021
revised:
17
05
2021
accepted:
04
06
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of chronic liver disease that accompanies obesity and the metabolic syndrome. Excess fructose consumption can initiate or exacerbate NAFLD in part due to a consequence of impaired hepatic fructose metabolism. Preclinical data emphasized that fructose-induced altered gut microbiome, increased gut permeability, and endotoxemia play an important role in NAFLD, but human studies are sparse. The present study aimed to determine if two weeks of excess fructose consumption significantly alters gut microbiota or permeability in humans. We performed a pilot double-blind, cross-over, metabolic unit study in 10 subjects with obesity (body mass index [BMI] 30-40 mg/kg/m Routine blood, uric acid, liver function, and lipid measurements were unaffected by the fructose intervention. The fecal microbiome (including In contrast to rodent preclinical findings, excess fructose did not cause changes in the gut microbiome, metabolome, and permeability as well as endotoxemia in humans with obesity fed fructose for 14 days in amounts known to enhance NAFLD.
Identifiants
pubmed: 34422323
doi: 10.1017/cts.2021.801
pii: S2059866121008013
pmc: PMC8358846
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e143Subventions
Organisme : NIDDK NIH HHS
ID : K08 DK117064
Pays : United States
Informations de copyright
© The Association for Clinical and Translational Science 2021.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Am J Clin Nutr. 2013 Aug;98(2):349-57
pubmed: 23783298
Nat Chem Biol. 2016 Jun;12(6):452-8
pubmed: 27110680
Curr Opin Lipidol. 2013 Jun;24(3):198-206
pubmed: 23594708
Am J Physiol Gastrointest Liver Physiol. 2011 Feb;300(2):G202-6
pubmed: 21148401
J Clin Invest. 2009 May;119(5):1322-34
pubmed: 19381015
Gastroenterology. 2016 Oct;151(4):733-746.e12
pubmed: 27342212
Gastroenterology. 1983 Jan;84(1):26-9
pubmed: 6847852
Eur J Gastroenterol Hepatol. 2015 Jul;27(7):840-5
pubmed: 26043290
Gut. 2019 Aug;68(8):1417-1429
pubmed: 30782617
Clin Gastroenterol Hepatol. 2007 Aug;5(8):959-63
pubmed: 17625977
Nutrients. 2016 Sep 20;8(9):
pubmed: 27657120
J Clin Endocrinol Metab. 2011 Mar;96(3):861-8
pubmed: 21252253
Nutrients. 2018 Jun 13;10(6):
pubmed: 29899272
Int J Mol Sci. 2016 May 20;17(5):
pubmed: 27213358
J Nutr. 2017 May;147(5):770-780
pubmed: 28356436
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Genome Biol. 2014;15(12):550
pubmed: 25516281
Front Nutr. 2019 Apr 17;6:48
pubmed: 31058161
Medscape J Med. 2008 Jul 09;10(7):160
pubmed: 18769702
Front Endocrinol (Lausanne). 2018 Jul 05;9:366
pubmed: 30026731
PLoS One. 2015 Aug 05;10(8):e0134893
pubmed: 26244577
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Nutrients. 2018 Sep 06;10(9):
pubmed: 30200659
Public Health Nutr. 2016 Sep;19(13):2424-34
pubmed: 26932353
Aliment Pharmacol Ther. 2007 Feb 15;25(4):349-63
pubmed: 17217453
J Clin Endocrinol Metab. 2015 Jun;100(6):2434-42
pubmed: 25825943
Nutr Rev. 2005 May;63(5):133-57
pubmed: 15971409
Gastroenterology. 2017 Sep;153(3):743-752
pubmed: 28579536
Arch Toxicol. 2017 Apr;91(4):1545-1563
pubmed: 27995280
Annu Rev Nutr. 2018 Aug 21;38:41-67
pubmed: 29751733
Crit Rev Food Sci Nutr. 2010 Jan;50(1):53-84
pubmed: 20047139
Gastroenterology. 2019 Oct;157(4):1109-1122
pubmed: 31255652
Am J Prev Med. 2004 Oct;27(3):205-10
pubmed: 15450632
Nutrients. 2017 Nov 06;9(11):
pubmed: 29113135
Clin Microbiol Infect. 2016 May;22(5):464-5
pubmed: 26806255
Clin Chim Acta. 2013 Mar 15;418:97-101
pubmed: 23328210
Metabolism. 1999 Apr;48(4):520-4
pubmed: 10206448
Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232
pubmed: 26405687
J Nutr Biochem. 2015 Nov;26(11):1183-92
pubmed: 26168700
Am J Clin Nutr. 2008 Dec;88(6):1733S-1737S
pubmed: 19064538
Int J Mol Med. 2019 Mar;43(3):1487-1496
pubmed: 30628636
Cell. 2012 Aug 3;150(3):470-80
pubmed: 22863002
Am J Clin Nutr. 2019 Jul 1;110(1):139-149
pubmed: 31124558
J Formos Med Assoc. 2019 Feb;118(2):545-555
pubmed: 29490879
J Inflamm (Lond). 2010 Mar 30;7:15
pubmed: 20353583
Cell Mol Gastroenterol Hepatol. 2019;8(2):247-267
pubmed: 31004828
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
J Clin Invest. 1966 Mar;45(3):388-98
pubmed: 5904556
Sci Rep. 2019 Apr 5;9(1):5688
pubmed: 30952918
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078